Hydrochlorothiazide 12.5mg

DRUG4 trials

Sponsors

Boehringer Ingelheim, Cedars-Sinai Medical Center, University of Pisa, University of Kansas Medical Center

Conditions

Chronic PainDiabetes Mellitus, Type 2Diuretics Drug ReactionsGlucose Metabolism DisordersHypertensionRenal Function DisorderSCS

Early Phase 1

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

Active, not recruitingNCT04676399

University of Kansas Medical CenterChronic Pain, Diuretics Drug Reactions, Hypertension +1

Start: 2022-02-08End: 2027-12-31Target: 36Updated: 2025-09-05

Phase 4

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

WithdrawnNCT03640221

Cedars-Sinai Medical CenterDiabetes Mellitus, Type 2, Hypertension

Start: 2018-09-01End: 2020-08-31Updated: 2020-01-14

Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy

University of PisaGlucose Metabolism Disorders, Renal Function Disorder

Start: 2019-06-04End: 2020-04-01Updated: 2020-01-27

Unknown Phase

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

CompletedNCT01050062

Boehringer IngelheimHypertension

Start: 2010-01-31End: 2011-12-31Updated: 2014-05-01